Judah Frommer
Stock Analyst at Morgan Stanley
(3.89)
# 558
Out of 5,182 analysts
194
Total ratings
61.81%
Success rate
5.28%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KLRS Kalaris Therapeutics | Initiates: Overweight | $14 | $5.46 | +156.41% | 1 | Apr 16, 2026 | |
| IMMX Immix Biopharma | Initiates: Overweight | $20 | $9.30 | +115.05% | 1 | Mar 25, 2026 | |
| TRVI Trevi Therapeutics | Maintains: Overweight | $19 → $18 | $13.87 | +29.78% | 3 | Mar 18, 2026 | |
| ZBIO Zenas BioPharma | Maintains: Equal-Weight | $19 → $21 | $19.36 | +8.47% | 3 | Mar 17, 2026 | |
| RGNX REGENXBIO | Maintains: Overweight | $18 → $17 | $9.12 | +86.40% | 4 | Mar 6, 2026 | |
| BLTE Belite Bio | Maintains: Overweight | $191 → $201 | $154.85 | +29.80% | 2 | Mar 3, 2026 | |
| AGMB AgomAb Therapeutics NV | Initiates: Overweight | $28 | $11.20 | +150.00% | 1 | Mar 3, 2026 | |
| GMAB Genmab | Reinstates: Equal-Weight | $34 | $26.45 | +28.54% | 1 | Feb 16, 2026 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $101 → $145 | $117.61 | +23.29% | 4 | Jan 9, 2026 | |
| EVMN Evommune | Initiates: Overweight | $36 | $24.50 | +46.94% | 1 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $26 | $40.96 | -36.52% | 2 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $43 | $32.31 | +33.09% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $31 → $22 | $27.99 | -21.40% | 3 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $6 | $9.09 | -33.99% | 2 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $21.67 | +61.51% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $1.93 | +55.44% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $0.93 | +4,199.69% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $2.38 | +446.22% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $13.43 | +123.38% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $33.08 | -30.47% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $65.15 | -23.25% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $21.49 | +556.12% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $4.14 | +117.39% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $28.43 | -22.62% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $6.47 | +8.19% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $7.36 | +8.70% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $128.79 | -64.28% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $3.11 | +125.08% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $19.13 | +187.51% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $133.26 | -65.48% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $88.69 | -44.75% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $1,011.70 | -63.43% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $93.04 | -66.68% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $74.05 | +2.63% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $114.43 | +59.05% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $94.67 | +13.02% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $85.61 | +10.97% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $16.62 | +8.30% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $230.52 | -49.68% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $93.51 | -59.36% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $81.19 | -72.90% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $67.77 | -48.35% | 9 | Apr 29, 2020 |
Kalaris Therapeutics
Apr 16, 2026
Initiates: Overweight
Price Target: $14
Current: $5.46
Upside: +156.41%
Immix Biopharma
Mar 25, 2026
Initiates: Overweight
Price Target: $20
Current: $9.30
Upside: +115.05%
Trevi Therapeutics
Mar 18, 2026
Maintains: Overweight
Price Target: $19 → $18
Current: $13.87
Upside: +29.78%
Zenas BioPharma
Mar 17, 2026
Maintains: Equal-Weight
Price Target: $19 → $21
Current: $19.36
Upside: +8.47%
REGENXBIO
Mar 6, 2026
Maintains: Overweight
Price Target: $18 → $17
Current: $9.12
Upside: +86.40%
Belite Bio
Mar 3, 2026
Maintains: Overweight
Price Target: $191 → $201
Current: $154.85
Upside: +29.80%
AgomAb Therapeutics NV
Mar 3, 2026
Initiates: Overweight
Price Target: $28
Current: $11.20
Upside: +150.00%
Genmab
Feb 16, 2026
Reinstates: Equal-Weight
Price Target: $34
Current: $26.45
Upside: +28.54%
ABIVAX Société Anonyme
Jan 9, 2026
Maintains: Overweight
Price Target: $101 → $145
Current: $117.61
Upside: +23.29%
Evommune
Dec 1, 2025
Initiates: Overweight
Price Target: $36
Current: $24.50
Upside: +46.94%
Jul 2, 2025
Maintains: Equal-Weight
Price Target: $25 → $26
Current: $40.96
Upside: -36.52%
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $32.31
Upside: +33.09%
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $27.99
Upside: -21.40%
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $9.09
Upside: -33.99%
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $21.67
Upside: +61.51%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $1.93
Upside: +55.44%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $0.93
Upside: +4,199.69%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $2.38
Upside: +446.22%
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $13.43
Upside: +123.38%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $33.08
Upside: -30.47%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $65.15
Upside: -23.25%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $21.49
Upside: +556.12%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $4.14
Upside: +117.39%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $28.43
Upside: -22.62%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $6.47
Upside: +8.19%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $7.36
Upside: +8.70%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $128.79
Upside: -64.28%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $3.11
Upside: +125.08%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $19.13
Upside: +187.51%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $133.26
Upside: -65.48%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $88.69
Upside: -44.75%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $1,011.70
Upside: -63.43%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $93.04
Upside: -66.68%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $74.05
Upside: +2.63%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $114.43
Upside: +59.05%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $94.67
Upside: +13.02%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $85.61
Upside: +10.97%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $16.62
Upside: +8.30%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $230.52
Upside: -49.68%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $93.51
Upside: -59.36%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $81.19
Upside: -72.90%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $67.77
Upside: -48.35%